Direct Answer
SEC EDGAR classifies Quest Diagnostics under SIC code 8071 (Services-Medical Laboratories). Among Swoopr's S&P 500 Equal Weight companies, 16 others share that classification; by latest reported revenue, Quest Diagnostics ranks 2 of 17. A filing classification is a starting point: a company's real competitors depend on its segments, which its 10-K describes.
How Does Quest Diagnostics Compare With Its Peers?
| Company | Revenue (latest FY) | Revenue growth | Operating margin | Net margin |
|---|---|---|---|---|
| Labcorp (LH) | $14.0 billion FY2025 | 7.2% | 9.9% | 6.3% |
| Quest Diagnostics (DGX) | $11.0 billion FY2025 | 11.8% | 14.1% | 9.0% |
| Natera Inc. (NTRA) | $2.3 billion FY2025 | 35.9% | -13.4% | -9.0% |
| Guardant Health Inc. (GH) | $982 million FY2025 | 32.9% | -44.5% | -42.4% |
| Caris Life Sciences Inc. (CAI) | $812 million FY2025 | 97.0% | 5.6% | -8.4% |
| CareDx Inc. (CDNA) | $380 million FY2025 | 13.8% | -8.1% | -5.6% |
| Castle Biosciences Inc. (CSTL) | $344 million FY2025 | 3.7% | -12.4% | -7.0% |
| Fulgent Genetics Inc. (FLGT) | $323 million FY2025 | 13.8% | -28.2% | -18.8% |
| BillionToOne Inc. (BLLN) | $305 million FY2025 | 100.0% | 5.3% | 2.4% |
| GRAIL Inc. (GRAL) | $147 million FY2025 | 17.2% | -382.0% | -277.5% |
| Biodesix Inc. (BDSX) | $88 million FY2025 | 24.1% | -31.5% | -39.9% |
| Personalis Inc. (PSNL) | $70 million FY2025 | -17.7% | -126.4% | -116.7% |
| Exagen Inc. (XGN) | $67 million FY2025 | 19.7% | -21.1% | -30.0% |
| American Shared Hospital Services (AMS) | $28 million FY2025 | -0.9% | -12.8% | -5.5% |
| YD Bio Limited (YDES) | $596,817 FY2025 | 16.9% | -883.3% | -1392.6% |
| Sera Prognostics Inc. (SERA) | $81,000 FY2025 | 5.2% | -45066.7% | -39417.3% |
| Aclarion Inc. (ACON) | $75,730 FY2025 | 65.6% | -9312.5% | -9551.9% |
Revenue growth compares each company's latest fiscal year with the one before. Fiscal years do not always end on the same date, so treat close comparisons with care.
How Does Quest Diagnostics Rank Among All SEC Filers in Its Industry Code?
17 companies with annual reports in Swoopr's SEC dataset share SIC code 8071 (Services-Medical Laboratories), a wider group than the S&P 500 Equal Weight companies above. Ranks run from 1 (highest) and use each company's latest fiscal year, in U.S. dollars.
| Measure | Quest Diagnostics | Median of filers | Rank |
|---|---|---|---|
| Revenue | $11.0 billion | $305 million | 2 of 17 |
| Revenue growth | 11.8% | 16.9% | 12 of 17 |
| Operating margin | 14.1% | -21.1% | 1 of 17 |
| Net margin | 9.0% | -18.8% | 1 of 17 |
A SIC code reflects the filer's main business as the SEC records it, so the group mixes companies of very different size; the median is a better guide than the average, and a rank near the top by revenue says nothing about quality.
Where These Numbers Come From
Every figure on this page is a value Quest Diagnostics reported in its own SEC filings, read from the SEC's XBRL data (accession 0001022079-26-000015 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.
Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.
Frequently Asked Questions
Who are Quest Diagnostics's competitors?
Companies sharing Quest Diagnostics's SEC classification (SIC code 8071 (Services-Medical Laboratories)) include Labcorp (LH), Natera Inc. (NTRA), Guardant Health Inc. (GH), Caris Life Sciences Inc. (CAI), CareDx Inc. (CDNA). Its 10-K names the competitors it considers most relevant.
How does Quest Diagnostics compare with its peers on margins?
Quest Diagnostics's fiscal 2025 operating margin was 14.1%, against a peer median of -24.7%.
How are these peers chosen?
By the SEC Standard Industrial Classification code each company files under, within Swoopr's S&P 500 Equal Weight company set, falling back to the two-digit major group when fewer than two companies share the exact code. Classification codes are broad, so read the peer list as a screen, not a verdict.
How does Quest Diagnostics rank among all companies in its SEC industry?
Among 17 SEC filers under SIC code 8071, Quest Diagnostics ranks 2 by latest revenue, and 1 of 17 by operating margin (14.1% against a median of -21.1%).